Stocks · News reference

BioVie shares are trading higher after the company announced the presentation of Phase 2 Long COVID data showing statistically significant improvements in fatigue and cognitive measures in certain patient subgroups treated with bezisterim.

Oct 19, 2026, 6:37 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 19, 2026, 12:08 PMBenzinga Newsdesk
BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of
BIVI
BenzingaOct 14, 2026, 12:07 PMBenzinga Newsdesk
BioVie To Present Phase 2 Bezisterim Data In Long COVID, Parkinson’s At Neurology Conference October 18-19
BIVI
BenzingaSep 15, 2026, 4:21 PMVandana Singh
What's Going On With BioVie Stock on Tuesday?
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
BIVI